Opinion
Video
Author(s):
The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
Revisit Every OncLive On Air Episode From May 2024
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC
FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC